No Data
No Data
We Think C4 Therapeutics (NASDAQ:CCCC) Can Afford To Drive Business Growth
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)
C4 Therapeutics Inc (CCCC) Q1 2024 Earnings: Navigating Challenges With Strategic Collaborations
On May 8, 2024, C4 Therapeutics Inc (NASDAQ:CCCC) released its 8-K filing, detailing the financial results for the first quarter ended March 31, 2024.
Express News | Wells Fargo Maintains Equal-Weight on C4 Therapeutics, Raises Price Target to $8
C4 Therapeutics Is Maintained at Buy by Stifel
C4 Therapeutics Is Maintained at Buy by Stifel
C4 Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 113.41% Stifel $13 → $14 Maintains Buy 02/26/2024 21.95% Morgan Stanley $1 → $8 Maintains Equal
No Data